HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Appropriators Continue Pressing US FDA To Conduct Surprise In-Person Inspections

Executive Summary

Omnibus package also gives FDA expanded authority over nicotine products and creates President Biden’s Advanced Research Projects Agency for Health.

You may also be interested in...



Senate Proposes Smaller Boost Than House For FDA FY2023 Appropriation

Senate Appropriations Committee proposes $1.185bn to CFSAN and $2.19bn to CDER, both levels short of House appropriators passed in June. FDA requested $30.36m in user fees from monograph drugs but no amount was specified in Senate draft bill.

Remote Inspections: Stakeholders Seek Clarity As Some At US FDA Struggle With Process

Some lawmakers want FDA to prioritize in-person visits, but others are complaining that more remote inspections are needed because approvals are being delayed.

ARPA-H: New Health Research Agency Faces Old Concerns About Disrupting Private Investment

Proposed Advanced Research Project Agency for Health also needs to distinguish itself from NCATS, which faced many of the same questions when it was created a decade ago. Disagreements also persist about whether ARPA-H should be housed in NIH or HHS.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel